Drug firm Roche India on Thursday said it has launched Atezolizumab used for the treatment of small cell lung cancer in India after getting nod from Drugs Controller General of India.
"Atezolizumab is the first cancer immunotherapy to receive an approval in India for the first line treatment of extensive-stage small cell lung cancer (ES-SCLC) when given in combination with chemotherapy," Roche India said in a statement.
The cancer immunotherapy harnesses the person's immune system to combat cancer more effectively for better results, it added.
"Roche is committed to bring to India all the innovations being developed in its pipeline, to benefit patients," Lara Bezerra, chief purpose officer at Roche Products (India) said.
Launching Atezolizumab is an important step for small cell lung cancer patients in India, she added.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.